CHMP, Sarclisa and multiple myeloma
Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
clinicaltrialsarena on MSN15h
GSK reports positive outcomes from Phase III multiple myeloma treatment trialGSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
News Medical on MSN1d
Interactive atlas unveils immune changes in multiple myelomaMultiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
The department used its new system for determining whether a condition is service-connected to give affected veterans access ...
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...
High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
Healthcare Asia on MSN22h
Pharmaceutical firms eye multiple myeloma amidst rising incidence ratesThe increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback